DUBLIN–(BUSINESS WIRE)–The “5-HT2C
Agonist -Pipeline Insight, 2019” drug pipelines has been added
to ResearchAndMarkets.com’s offering.
5-HT2C Agonist – Pipeline Insight, 2019 report offers comprehensive
insights of the pipeline (under development) therapeutics scenario and
growth prospects across 5-HT2C Agonist development. The report provides
detailed coverage of the pipeline landscape for this mechanism of
action, equipped with data from multiple sources with complete pipeline
analysis by developmental stage, associated indications, route of
administration and molecule type.
Descriptive coverage of pipeline development activities for 5-HT2C
Agonist – Pipeline therapeutics development coverage provides
descriptive product profiles including (but not limited to) drug
description, product development and R&D activities encompassing
clinical and pre-clinical studies, designations, collaborations,
licensing deals, grants, technologies and patent details.
The report assesses the active 5-HT2C Agonist pipeline products by
developmental stage, product type, molecule type, and administration
route.
Scope of the report
-
Provides a snapshot of the therapeutics pipeline activity for 5-HT2C
Agonist -
Features the 5-HT2C Agonist pipeline across the complete product
development cycle including all clinical and non-clinical stages -
Offers detailed therapeutic product profiles of 5-HT2C Agonist with
key coverage of developmental activities including licensing &
collaboration deals, patent details, designations, technologies,
indications and chemical information -
Therapeutic assessment of the active pipeline products by stage,
product type, molecule type, and route of administration -
Coverage of dormant and discontinued pipeline projects across 5-HT2C
Agonist
Key Topics Covered:
1. Report Introduction
2. 5-HT2C Agonist – Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for 5-HT2C Agonist
4. Comparative Analysis
5. 5-HT2C Agonist Pipeline Products in Clinical Stages
- Product Description
- Research and Development
- Product Development Activities
6. 5-HT2C Agonist Pipeline Products in Non-clinical Stages
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment: Active Products
- Pipeline Assessment by Route of Administration
- Pipeline Assessment by Stage and Route of Administration
- Pipeline Assessment by Molecule Type
- Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline Products
- Product Description
- Research and Development
- Product Development Activities
- Reason for dormancy/discontinuation
Companies Mentioned
- Wyeth
- Otsuka Pharmaceutical
- Epygenix Therapeutics
- Zysis
- Arena Pharmaceuticals
- Biovitrum
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/fcyrcc
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs